Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines
- PMID: 7586802
- DOI: 10.1007/BF00118183
Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines
Abstract
Secretion of plasminogen activators (PA) has been shown to be an important method by which cells can initiate degradation of the extracellular matrix (ECM). In this study we have examined the PA production of two murine cell lines, KHT-LP1, a fibrosarcoma and SCC-VII, a squamous cell carcinoma, and have found a high degree of clonal heterogeneity. Our method for assaying PA activity measures the PA activity of small colonies of cells derived from single cells, using an in vitro fibrin/agarose PA assay in which colonies with PA activity form discernable 'halos' in the fibrin/agarose semisolid growth medium. When these small colonies of cells were disassociated and the component cells were reassayed for PA activity it was again found to be heterogeneous, suggesting that this property can be generated during the growth of the colonies. KHT-LP1 cells derived from single cell clones were assayed for PA activity to determine the rate at which this phenotype was produced. It was found that the rate of formation of the PA activity phenotype was 6.5 x 10(-6) events per cell generation. The component cells of colonies which initially demonstrated high PA activity produced more PA activity than the component cells of the colonies that had low PA activity. This suggests that some aspects of the phenotype may be more stable than others. To examine whether the addition of lethally irradiated cells could stabilize the phenotype we determined whether fibrin/agarose PA assays supplemented with lethally irradiated cells would reduce the heterogeneity of PA activity. The results indicated that the heterogeneity was not reduced, and there was an increase in the average amount of PA activity.
Similar articles
-
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.Clin Exp Metastasis. 1989 Mar-Apr;7(2):243-50. doi: 10.1007/BF01787027. Clin Exp Metastasis. 1989. PMID: 2920477
-
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):989-92. doi: 10.1001/archotol.1994.01880330067012. Arch Otolaryngol Head Neck Surg. 1994. PMID: 8074827
-
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.Cancer Commun. 1990;2(5):189-99. Cancer Commun. 1990. PMID: 2142433
-
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.Gynecol Oncol. 1988 Sep;31(1):103-12. doi: 10.1016/0090-8258(88)90276-4. Gynecol Oncol. 1988. PMID: 3410341
-
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.Cancer Res. 1993 Jan 1;53(1):147-52. Cancer Res. 1993. PMID: 8380125
Cited by
-
Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion.Clin Exp Metastasis. 1997 Jan;15(1):19-25. doi: 10.1023/a:1018428105463. Clin Exp Metastasis. 1997. PMID: 9009102
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials